Currently, ESC/EACTS guidelines recommend prasugrel as an initial P2Y12 inhibitor over clopidogrel, unless the patients are ≥ 75 years of age, with low body weight (<60 kg), or previous history of transient ischemic attack or stroke [4]. The gene discussed is P2RY12; the disease is stroke disorder.